Medical and economical consequences of extension of medicamentally support program for patients with COPD in Russia


DOI: https://dx.doi.org/10.18565/therapy.2019.5.36-44

Malyavin A.G., Avksentieva M.V., Babak S.L., Dzanaeva A.V.

1) A.I. Yevdokimov Moscow State University of medicine and dentistry of the Ministry of Healthcare of Russia 2) I.M. Sechenov First Moscow State medical University» of the Ministry of Healthcare of Russia (Sechenov University)
The aim of the study was to analyze the impact on the healthcare budget of Russia from providing adult patients with chronic obstructive pulmonary disease (COPD) with basic therapy, taking into account the expected decrease in the frequency of exacerbations of the disease and the hospitalizations resulting from them.
Material and methods. The model calculates the direct medical costs of preferential medication and treatment of exacerbations in COPD patients in the current situation and in the coverage of all COPD patients by basic therapy.
Results and conclusions. The costs of providing all COPD patients with the recommended basic drug therapy on an outpatient basis are largely compensating by a decrease in the cost of treating exacerbations: the costs of drug provision should increase by 13.9 billion rubles in comparison with the current situation, when the costs of providing medical care to patients with exacerbations is reduced by 9.6 billion rubles. As a result, the difference in direct medical costs, or the necessary additional investments, is 4.3 billion rubles. The price of drugs used for basic therapy has the greatest impact on the size of the required additional investments.
Keywords: medicamentary supply, budget impact analysis, basic therapy, chronic obstructive pulmonary disease
Read entire article

Literature


  1. World Health Organization. Evidence-informed policy-making. 2016. http://www.who.int/evidence (http://www.goldcopd.com)

  2. Lopez C.J., Murray A.D. et al. Alternative projections of mortality and disability by course 1990–2020: Global Burden of Disease Study. Lancet. 1997; 349: 1498–1504.

  3. Adeloye D., Chua S., Lee C. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. Journal of global health. 2015; 5(2): 020415.

  4. Lamprecht B., McBurnie M.A., Vollmer W.M. et al. BOLD Collaborative Research Group: COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest. 2011; 139: 752–63. (http://www.goldcopd.com)

  5. Общая заболеваемость взрослого населения России в 2016 г. Статистические материалы. Часть IV. ФГБУ ЦНИИОИЗ, 2017.

  6. Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J COPD. 2014; 12: 963–74. (http://www.goldcopd.com)

  7. Клинические рекомендации. Хроническая обструктивная болезнь легких МКБ-10: J44 Год утверждения (частота пересмотра): 2018 (пересмотр каждые 3 года). ID: КР603 Российское респираторное общество.

  8. Недогода С.В., Барыкина И.Н., Саласюк А.С. с соавт. Фармакоэкономический анализ применения фиксированной комбинации тиотропия бромид + олодатерол в качестве поддерживающей терапии у пациентов с ХОБЛ в Российской Федерации. Медицинские технологии. Оценка и выбор. 2018; 2(32): 81–93.

  9. Дьяков И.Н., Зырянов С.К. Фармакоэкономическая целесообразность включения препарата гликопиррония бромид в программу обеспечения необходимыми лекарственными средствами пациентов с хронической обструктивной болезнью легких. Медицинские технологии. Оценка и выбор. 2017; 1(27): 35–45.

  10. Гайгольник Т.В., Демко И.В., Бочанова Е.Н., Крапошина А.Ю., Гордеева Н.В., Соловьева И.А. Фармакоэкономический анализ затрат на обеспечение льготными лекарственными препаратами больных хронической обструктивной болезнью легких на территории Красноярского края. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2016; 9(2): 49–59.

  11. The economic burden of lung disease. In: European Lung White Book. https://www.erswhitebook.org/chapters/the-economic-burden-of-lung-disease/

  12. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2019 Report. https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf

  13. Постановление Правительства РФ от 10.12.2018 № 1506 «О Программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2019 год и на плановый период 2020 и 2021 годов».

  14. Государственный реестр предельных отпускных цен производителей на лекарственные препараты, включенные в перечень жизненно необходимых и важнейших лекарственных препаратов (по состоянию на 25.03.2019). https://grls.rosminzdrav.ru/Default.aspx

  15. Purdy S., Griffin T., Salisbury C., Sharp D. Ambulatory care sensitive conditions: terminology and disease coding need to be more specific to aid policy makers and clinicians. Public Health. 2009 Feb; 123(2): 169–73. doi: 10.1016/j.puhe.2008.11.001. Epub 2009 Jan 13.

  16. Fletcher M., van der Molen T., Barnes N., Walsh J. et al. COPD: The New Workplace Epidemic. Updated September 2011. https://www.copdfoundation.org/pdfs/copd-uncovered-report-2011.pdf


About the Autors

Andrey G. Malyavin, MD, professor of the Department of phthisiology and pulmonology of A.I. Yevdokimov Moscow State University of medicine and dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str. Tel.: +7 (916) 547-83-73. E-mail: maliavin@mail.ru
Maria V. Avksentieva, MD, professor of Higher School of Healthcare management of I.M. Sechenov First Moscow State medical University of the Ministry of Healthcare of Russia. Address: 109004, Moscow, 28/1 Aleksandr Solzhenitsyn Str. Tel.: +7 (499) 763-68-05.
Sergey L. Babak, MD, professor of the Department of phthisiology and pulmonology of A.I. Yevdokimov Moscow State University of medicine and dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str. Tel.: +7 (903) 729-62-33. E-mail: sergbabak@mail.ru
Alla v. Dzanaeva, staff member of the Department of regulation in the field of circulation of pharmaceutical products and medical devices of I.M. Sechenov First Moscow State medical University of the Ministry of Healthcare of Russia. Address: 125018, Moscow, 1/17 Skladochnaya Str. Tel.: +7 (495) 656-27-57.


Similar Articles

Back to Content

Бионика Медиа